Fig 1: Receiver operating characteristic (ROC) curves, characterizing the quality of the ROC models for dividing all patients with mammary adenocarcinoma (MAC) into 2 groups—patients with metastases to regional lymph nodes and patients without metastases, by values granulocyte macrophage colony-stimulating factor (GM-CSF; pg/mL), CSF2RA (colored area, %), and KGM-CSF/CSF2RA (conventional units; A) for all patients: for GM-CSF area under the curve (AUC) = 0.633, for CSF2RA AUC = 0.573, for KGM-CSF/CSF2RA AUC = 0.625; (B) provided that highly differentiated tumor cells in MAC biopsy specimens were in the range of 10% to 30% for GM-CSF AUC = 0.692, for CSF2RA AUC = 0.514, for KGM-CSF/CSF2RA AUC = 0.653. ROC curves, characterizing the quality of the ROC models by dividing the 2 groups of patients—with metastases to regional lymph nodes and without metastases, by values (B) IL-1ß (pg/mL), IL1R2 (colored area, %), and KIL-1ß/IL1R2 (conventional units); (C) for all patients: for IL-1ß AUC = 0.616, for IL1R2 AUC = 0.226, KIL-1ß/IL1R2 AUC = 0.770; (D) provided that highly differentiated tumor cells in MAC biopsy specimens were in the range of 10% to 30%: for IL-1ß AUC = 707.0, for IL1R2 AUC = 0.093, for KIL-1ß/IL1R2 AUC = 0.913.